Heart failure: Audit and feedback activity 2 – Pharmacological management of HFrEF

Heart failure: Audit and feedback activity 3 – Ongoing management

Coming soon - due to be launched at the end of June 2022

Chronic kidney disease: Audit and feedback activity 1 – Screening

This activity allows you to screen patients at risk of CKD and identify those with early signs of the disease.

Chronic kidney disease: Audit and feedback activity 2 – Diagnosis and management

This activity allows you to review your approach to the diagnosis and the management of CKD.

Chronic kidney disease: Audit and feedback activity 3 – Pharmacological management

This activity allows you to optimise your prescribing for CKD, including the use of:

  • angiotensin-converting enzyme (ACE) inhibitors / angiotensin II receptor blockers (ARBs) and
  • sodium-glucose co-transporter-2 (SGLT2) inhibitors to treat those with CKD and type 2 diabetes.

Heart failure: Audit and feedback activity 1 – Diagnosis and documentation